Description

This issue of Vital Signs, released on February 26, 2007, provides a strategic overview of the potential impact of changes to the warfarin drug label on pharmacogenetic testing. Additionally, an emerging company profile is provided for Tm Bioscience Corporation, a clinical diagnostics company involved in manufacturing and marketing genetic tests. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of February 12 - February 16, 2007.